Quality of life and patient-perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed-dose combination Cal/BD foam: a post-hoc analysis of PSO-LONG

Psoriasis

Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post-hoc analysis of the BRIDGE study

J Eur Acad Dermatol Venereol.

Van de Kerkhof PCM, Loewe R, Mrowietz U, Falques M, Pau-Charles I, Szepietowski JC

doi: 10.1111/jdv.15922.

COMMENTED

Psoriasis

Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies

Am J Clin Dermatol.

Armstrong AW, Reich K, Foley P, Han C, Song M, Shen YK, You Y, Papp KA

doi: 10.1007/s40257-018-0396-z.

Psoriasis

Effect of Secukinumab on Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: a Post hoc Analysis of the SUPREME Study

Acta Derm Venereol

Talamonti M, Malara G, Natalini Y, Bardazzi F, Conti A, Chiricozzi A, Mugheddu C, Gisondi P, Piaserico S, Pagnanelli G, Amerio P, Potenza C, Cantoresi F, Concetta Fargnoli M, Balato A, Loconsole F, Offidani A, Bonifati C, Prignano F, Bartezaghi M, Rausa A, Aloisi E, Orsenigo R, Costanzo A, the SUPREME Study Group.

doi: 10.2340/00015555-3712

Psoriasis

Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post-hoc analysis through 64 weeks from reSURFACE 1 trial

J Eur Acad Dermatol Venereol

Warren RB, Carrascosa JM, Fumero E, Schoenenberger A, Lebwohl MG, Szepietowski JC, Reich K

doi: 10.1111/jdv.16964

Psoriasis

A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis

J Eur Acad Dermatol Venereol

Pinter A, Green LJ, Selmer J, Praestegaard M, Gold LS, Augustin M, trial investigator group.

doi: 10.1111/jdv.17734

Psoriasis

Tildrakizumab Efficacy and Impact on Quality of Life Up to 52 Weeks in Patients with Moderate-to-Severe Psoriasis: A Pooled Analysis of Two Randomized Controlled Trials

J Eur Acad Dermatol Venereol.

Blauvelt A, Sofen H, Papp K, Gooderham M, Tyring S, Zhao Y, Lowry S, Mendelsohn A, Parno J, Reich K

doi: 10.1111/jdv.15862.

Psoriasis

Secukinumab treatment leads to normalisation of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: The PROSE study results

J Eur Acad Dermatol Venereol.

Augustin M, Dauden E, Mrowietz U, Konstantinou MP, Gerdes S, Kingo K, Szepietowski JC, Perrot JL, Cuccia A, Rissler M, Gathmann S, Sieder C, Orsenigo R, Jagiello P, Bachhuber T

doi: 10.1111/jdv.16632.

Atopic Dermatitis

Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life, and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomised trial

J Eur Acad Dermatol Venereol

Wollenberg A, Nakahara T, Maari C, Peris K, Lio P, Augustin M, Silverberg JI, Rueda MJ, DeLozier AM, Pierce E, Yang FE, Sun L, Ball S, Tauber M, Paul C

doi: 10.1111/jdv.17278

Psoriasis

Efficacy of ixekizumab on nail psoriasis in pediatric patients with moderate-to-severe psoriasis: a post-hoc analysis from IXORA-PEDS

J Eur Acad Dermatol Venereol

Seyger MMB, Reich A, El Baou C, Schuster C, Riedl E, Paller AS

doi: 10.1111/jdv.17564

Related content

Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post-hoc analysis of the BRIDGE study

Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies

Effect of Secukinumab on Perception of Anxiety and Depression in Patients with Moderate to Severe Psoriasis: a Post hoc Analysis of the SUPREME Study

Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post-hoc analysis through 64 weeks from reSURFACE 1 trial

A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy and safety of a novel, fixed dose calcipotriene and betamethasone dipropionate cream for the topical treatment of plaque psoriasis

Tildrakizumab Efficacy and Impact on Quality of Life Up to 52 Weeks in Patients with Moderate-to-Severe Psoriasis: A Pooled Analysis of Two Randomized Controlled Trials

Secukinumab treatment leads to normalisation of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: The PROSE study results

Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life, and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomised trial

Efficacy of ixekizumab on nail psoriasis in pediatric patients with moderate-to-severe psoriasis: a post-hoc analysis from IXORA-PEDS